Concepedia

Author

Bent Winding

Swedish Orphan Biovitrum (Sweden)

Also Known As

B Winding, B. Winding, Bent Winding

36

Publications

1.2K

Citations

17

H-Index

39

Concepts

All Affiliations

Swedish Orphan Biovitrum (Sweden)Sanofi (United States)Center for Clinical & Basic ResearchChildren's Health Ireland at CrumlinMichigan State University
BW

About

Bent Winding is an author at Swedish Orphan Biovitrum (Sweden) specializing in medicine, cell biology, and extracellular matrix.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

401

2

Health Sciences

2

2

201

3

Engineering

1

1

57

4

Biochemistry

1

1

24

5

Biomedical Engineering

1

1

57

Bent Winding

×

17

Publications

928

Citations

16

H-Index

YearCitations

Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic Lesions

Olivier Peyruchaud, Bent Winding, Isabelle Pécheur,

Journal of Bone and Mineral Research

2001

172

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Annette von Drygalski, Pratima Chowdary, Roshni Kulkarni,

New England Journal of Medicine

2023

160

Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.

Larry Pederson, Bent Winding, Niels T. Foged,

PubMed

1999

92

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Beatrice Nolan, Johnny Mahlangu, Ingrid Pabinger,

Haemophilia

2020

72

Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Bent Winding, Róisı́n NicAmhlaoibh, Henriette Misander,

PubMed

2002

67

Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay

Niels T. Foged, Jean‐Marie Delaissé, Hou Peng,

Journal of Bone and Mineral Research

1996

57

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

John Pasi, Kathelijn Fischer, Margaret V. Ragni,

Haemophilia

2020

44

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor <scp>VIII</scp> Fc fusion protein

Johannes Oldenburg, Roshni Kulkarni, Alok Srivastava,

Haemophilia

2017

43

Pituitary adenylyl cyclase‐activating polypeptides and vasoactive intestinal peptide inhibit bone resorption by isolated rabbit osteoclasts

Bent Winding, A. Wiltink, NT Foged

Experimental Physiology

1997

37

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results

Christoph Königs, Margareth C. Ozelo, Amy L. Dunn,

Blood

2022

29

Page 1